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Abstract: The aim of this work was to evaluate the effectiveness of mesoporous clays or silicas to
develop fast-dissolving glyburide tablets based on a liquisolid approach. Selected clay (Neusilin®US2)
and silica (Aeroperl®300) allowed preparation of innovative drug liquisolid systems containing
dimethylacetamide or 2-pyrrolidone as drug solvents, without using coating materials which are
necessary in conventional systems. The obtained liquisolid powders were characterized for solid-state
properties, flowability, compressibility, morphology, granulometry, and then used for directly
compressed tablet preparation. The developed liquisolid tablets provided a marked drug dissolution
increase, reaching 98% dissolved drug after 60 min, compared to 40% and 50% obtained from a reference
tablet containing the plain drug, and a commercial tablet. The improved glyburide dissolution was
attributed to its increased wetting properties and surface area, due to its amorphization/solubilization
within the liquisolid matrix, as confirmed by DSC and PXRD studies. Mesoporous clay and silica,
owing to their excellent adsorbent, flow, and compressibility properties, avoided use of coating
materials and considerably improved liquid-loading capacity, reducing the carrier amount necessary
to obtain freely flowing powders. Neusilin®US2 showed a superior performance than Aeroperl®300
in terms of the tablet’s technological properties. Finally, simplicity and cost-effectiveness of the
proposed approach make it particularly advantageous for industrial scale-up.
Keywords: mesoporous clay; Neusilin; aeroperl; liquisolid technique; glyburide; dissolution improvement
1. Introduction
Glyburide (GLY) belongs to the second generation of sulfonylurea antidiabetic drugs, and it is
one of the most widely utilized oral hypoglycemic agents [1]. Moreover, its ability to prevent cerebral
ischemia and hemorrhagic stroke has been recently proved [2,3], and from 2015 it has been included in
the model list of Essential Medicines of World Health Organization [4]. Due to its high permeability but
very low aqueous solubility [5], GLY is classified as a class II drug according to the biopharmaceutical
classification system [6]. As known, the dissolution rate of poorly water-soluble drugs often represents
the main limiting factor in their absorption rate [6,7]. Clinical studies evidenced a variable in vitro
dissolution, in vivo bioavailability, and the hypoglycaemic effect of GLY from different commercial
tablets [8]. Problems of bio-inequivalence among pharmaceutically equivalent dosage forms of the
drug were confirmed by a multinational post-market comparative study of various marketed products
of the drug [9]. Such findings were found to be related to the unsatisfactory and variable dissolution
behavior of GLY, further supporting the previously reported problems of formulation-dependent oral
absorption of the drug [10].
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Despite the fact that several strategies have been investigated in an effort to improve the
dissolution performance of GLY, including complexation with cyclodextrins [11–13], solid dispersions
in hydrophilic carriers [14–16], micellar solubilization [17], and formulation of self-micro-emulsifying
drug delivery systems (SMEDDS) [18–20], at present, there are no commercial GLY products arising
from such approaches. As a result, the development of effective GLY tablets with optimized dissolution
behavior and ease of manufacture with industrial scale-up feasibility still remains a challenge and
would be an important and useful result.
The liquisolid technique is a recent and promising alternative approach for improving the
dissolution properties of poorly soluble drugs. This technique was initially used to transform liquid or
semi-solid drugs into free-flowing, non-adherent, and readily compressible powders by simple mixing
with suitable solid excipients [21]. Subsequently, the possibility of preparing liquisolid systems of solid
poorly soluble drugs by dissolving them in a non-volatile water-miscible solvent, and then converting
the liquid system in an apparently dry, well flowable powder, suitable for tableting, by mixing
with proper solid excipients referred as carrier and coating materials [22,23] has been considered.
The non-volatile solvents would remain on the carrier surface, so that the drug is kept within the
powder substrate in a solubilized, almost molecularly dispersed state, with a great increase in both its
wetting properties and surface area available for dissolution, and thus a consequent improvement
in release rate and bioavailability is expected [22,24,25]. The actual effectiveness of this technique in
improving the dissolution performance [26–30] and, consequently, the bioavailability [31–33] of several
poorly-soluble drugs has been shown. Moreover, in addition to its drug release enhancement ability,
the liquisolid strategy is particularly interesting and attractive because of the manufacturing process
simplicity, low production costs, and ease of scale-up to industrial tablet production. Compounds
such as various grades of cellulose derivatives, starch, and lactose are mainly used as carrier materials,
while Aerosil is the most used coating material [26–29,31].
Mesoporous clays and silicas represent interesting and versatile pharmaceutical excipients, due to
their numerous attractive features, such as large surface area and great loading ability, good flow and
tableting properties, joined to very low toxicity, and low cost [34–36]. The multifaceted applications of
clay materials in the pharmaceutical field have been carefully reviewed [37,38]. In particular, their
effective use as drug delivery systems to modulate, extend, and/or target drug release has been widely
described [39–43]. Furthermore, they also proved their effectiveness in enhancing the dissolution
behavior, and then the bioavailability of scarcely water-soluble drugs [44–46]. Mesoporous clays and
silicas can thus be considered as potentially suitable materials for liquisolid systems preparation.
Therefore, based on all these premises, we considered it worthy of interest to investigate the
effectiveness of the liquisolid approach in the development of fast dissolving tablets of GLY with
improved drug dissolution performance, by replacing the mixture of carrier and coating materials
commonly used for their formulation with suitable mesoporous silicas or clays which would be able to
simultaneously perform both such functions.
This novel strategy should enhance the applicability of the liquisolid technique in the
pharmaceutical field, making it possible to decrease the necessary amount of adsorbent material, and,
consequently, reducing the tablet final weight, known as the main limiting factor of this approach [47].
At the same time, it should facilitate the formulation scale-up from laboratory to industrial production,
enabling the simplification of liquisolid tablet development by decreasing the number of formulation
components (and the problems of their proper choice and of their relative w/w ratios).
With this aim, after selection of the most suitable non-volatile water-miscible solvent, based on
its better solubilizing power towards GLY, the efficacy as carrier-coating materials of two different
mesoporous silicas (i.e., Aeroperl®300/30 and Zeopharm®5170) and a mesoporous clay (Neusilin®US2)
was investigated. Various liquisolid systems were then prepared and fully characterized for solid-state
properties, flowability, compressibility, morphology, particle size, specific surface area, and then
used for the preparation of directly compressed tablets. The obtained liquisolid tablets were tested
for technological properties (mean weight, crushing strength, disintegration time) and their drug
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dissolution profile was compared to those of a reference conventional tablet formulation containing
the drug as such and of a commercial tablet (Gliboral®).
2. Materials and Methods
2.1. Materials
Micronized glyburide (mean particle size 1.66 µm) (GLY) was from Laboratori Guidotti S.p.A.
(Pisa, Italy). Glyburide has a pH-dependent solubility; its saturation solubility at 37 ± 0.5 ◦C was
determined at pH 1.1 (0.93 ± 0.3 mg/L), pH 6.8 (4.0 ± 0.2mg/L), pH 7.4 (14.9 ± 1.1 mg/L) and pH 8.5
(108.9 ± 10.1 mg/L) (n = 3).
Neusilin®US2 (synthetic magnesium alumino-metasilicate) was from Fuji Chemicals, Toyama,
Japan), Aeroperl®300 (colloidal silica) from Degussa (Munich, Germany), and Zeopharm®5170 (silicon
dioxide) from Huber Engineering Materials (Atlanta, GA, USA). Labrasol® (caprylocaproyl macrogol-8
glycerides) and Transcutol® (diethylene glycol monoethyl ether) were kindly donated by Gattefossé
Italia s.r.l. (Milano, Italy). Kollisolv® PYR (2-pyrrolidone, 2-PYR), Kolliphor®HS15 (macrogol 15
hydroxy-stearate), Kollisolv® PEG 400, Kollidon®CL (crospovidone) and Kollidon®VA 64F (copolymer
1vinyl-2-pyrrolidone vinylacetate 60/40) were from BASF Co. Ltd. (Ludwigshafen, Germany).
Glycofurol was from Alchymars (Milano, Italy), N,N-dimethylacetamide (DMA) from Carlo Erba
(Milano, Italy), Solketal® (1,2-Isopropylidene-rac-glycerol), benzyl benzoate and 1,3-butandiole from
Merck (Kenilworth, NJ, USA). Avicel®PH102 (microcrystalline cellulose) was from FMC Biopolymer
(Philadelphia, PA, USA), Explotab® (sodium starch glycolate) was from Penwest Pharmaceuticals
(Patterson, NY, USA), and Ceolus®KG802 (microcrystalline cellulose) from Asahi Kasei (Tokyo, Japan).
Mg stearate was from Peter Greven Fett Chemie (Bad Munsterefeil, Germany). Water was obtained
from a Milli-Q water purification system (Millipore, MA, USA). All other chemicals and reagents were
of analytical grade.
2.2. Solubility Studies
To select the most effective drug solvent for liquisolid systems formulation, the GLY solubility
in different non-volatile water-miscible solvents, namely Labrasol®, Transcutol®, Kolliphor®HS15,
PEG 400, Kollisolv®, Solketal®, Kollisolv®PYR (2-pyrrolidone, 2-PYR), N,N-dimethylacetamide
(DMA), benzyl benzoate and 1,3-butandiole, was evaluated. The minimum amount necessary to
solubilize 5 mg GLY (drug therapeutic dose) was determined by adding progressive aliquots of each
solvent to the exactly weighed drug amount, at room temperature. Only in the case of Kolliphor®HS15,
solid at room temperature, it was necessary to heat to 40 ◦C for obtaining its fusion. The stability of
GLY dissolved in the various solvents was checked by UV assay (UV/Vis 1601 Shimadzu, Tokyo, Japan)
at 300 nm of its concentration immediately after the solution preparation, and then every 30 days for
6 months.
2.3. Characterization of the Mesoporous Silicas and Clays
2.3.1. Apparent and Tapped Density
Apparent density (DA) and tapped density (DT) were evaluated according to the USP method,
using a PT-TD 300 instrument (Pharma Test, Hainburg, Germany) endowed with a standard 100 mL
graduated cylinder. Carr’s Index (CI) and Hausner Ratio (HR), indicative of the powder compressibility




; HR = DT1250/DA (1)
where DT1250 is the tapped density value obtained after 1250 taps of the cylinder.
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2.3.2. Powder Flowability
Powder flowability was determined by the Copley flow-test (Copley Scientific Ltd., Nottingham,
UK), evaluating the powder ability to freely flow through a circular orifice of known diameter.
The flowability index is given by the diameter (ranged from 4 to 26 mm) of the smallest hole through
which the powder falls freely (mean of three determinations).
2.3.3. Powder Compactability
Powder compactability was evaluated according to the Wells method [48]. Briefly, 3 samples were
prepared for each carrier, by weighing each time aliquots of 5 g of powder, adding 50 mg of Mg stearate
as a lubricant, and mixing in a V-mixer 3 min (samples A and B) or 30 min (sample C). From each
sample blend, five tablets (13 mm diameter) were then obtained, by compacting with a hydraulic press
500 mg powder, under 1 ton of pressure for 5 s (A and C) or 30 s (B). After 24 h, the tablets’ crushing
force (N) was measured (Schleuniger Hardness Tester model 6D, JB Pharmatron, Northampton, UK).
2.3.4. Specific Surface Area
Specific surface area measurements were performed according to the BET (Brunauer-Hemmet-Teller)
method using an automated ASAP (Accelerated Surface Area and Pore) 2010 adsorption analyzer
(Micromeritics, Norcross, GA, USA) at −196 ◦C. Before analysis, samples were degassed 24 h at room
temperature using a VacPrep apparatus (Micromeritics, Norcross, GA, USA).
2.4. Preparation of Liquisolid Systems
The drug was completely dissolved in the minimum necessary amount of solvent; then the drug
solution was put in a mortar, where the mesoporous silica (or clay) powder was gradually added,
under mixing, up to obtain an apparently dry powder.
2.5. Characterization of Liquisolid Systems
2.5.1. Particle Size Distribution
Granulometric analysis of the various liquisolid systems was performed using a Mastersizer 3000
Laser Particle Size (LPS) analyzer (Malvern Instruments, Malvern, UK). The particle size distribution
curves were obtained, and Dv10, Dv90, and Dv50 were evaluated, indicating, respectively, 10% or 90%
of the cumulative percent distribution and the median of the powder distribution curve. The SPAN
value, i.e., the curve distribution width around the median, was determined as an index of the powder
particle size homogeneity, by the following equation [49]:
SPAN = (Dv90 − Dv10)/Dv50 (2)
2.5.2. Differential Scanning Calorimetry (DSC)
Exactly weighed samples (5–10 mg, M3 microbalance, Mettler Toledo, Greifensee, Switzerland)
of pure drug and mesoporous silica or clay, and of the corresponding liquisolid systems were put in
pierced Al pans and scanned under static air at 10 ◦C/min from 30 to 300 ◦C using a TA4000 Stare
system (Mettler Toledo, Greifensee, Switzerland) equipped with a DSC 25 cell.
2.5.3. Powder X-Ray Diffractometry (PXRD)
Powder X-ray diffraction patterns of pure drug and mesoporous silica and clay and of the
corresponding liquisolid systems were recorded by a Bruker D8 Advance apparatus (Brucker, Billerica,
MA, USA), using a Cu Kα radiation and a graphite monochromator, under the following experimental
conditions: 40 mV voltage, 40 mA current, scan rate 0.05◦/s in the 2.5–50◦ 2Θ range, room temperature.
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2.5.4. Environmental Scanning Electron Microscopy (ESEM)
The morphological properties of the different liquisolid systems as well as of the final tablet
formulations were investigated using a Fei ESEM Quanta 200 Apparatus. Before performing the
analyses, samples were sputter-coated with gold-palladium under argon atmosphere, to make them
electrically conductive.
2.5.5. Dissolution Test
Dissolution rate experiments were performed according to the dispersed amount method.
A sample of each liquisolid system, equivalent to 5 mg drug, was added to 350 mL of pH 7.4 phosphate
buffer solution thermostated at 37 ± 0.5 ◦C, in a 400 mL beaker. A three-blade paddle was centrally
put in the beaker and rotated at 100 rpm. At given times, aliquots were withdrawn (syringe-filter,
pore size 0.45 µm), spectrometrically assayed at 300 nm (UV-Vis 1600 Shimadzu, Tokyo, Japan) for
drug content, and replaced with an equal fresh medium volume. A correction fort the cumulative
dilution was made. Each test was repeated four times (C.V. < 3.5%). Values of percent of drug dissolved
at 10, 30, and 60 min were analyzed by one-way analysis of variance (ANOVA) followed by the
Student-Newman-Keuls multiple comparison post-test (Graph Pad Prism 4.0 program, San Diego, CA,
USA). Differences were considered statistically significant when p < 0.05.
2.6. Tablets Preparation
Tablets containing 5 mg GLY as liquisolid system, accurately mixed with suitable excipients for
direct compression and Mg stearate as a lubricant, were prepared using a Manesty 2 alternative tableting
machine. A reference conventional tablet formulation containing the plain drug was also prepared.
2.7. Tablets Characterization
Appearance and morphologic analysis: the regularity of the tablets’ appearance was checked by
visual inspection. The morphology of the tablets’ surface was examined more in detail by ESEM analysis.
Weight uniformity: 20 tablets randomly taken from the batch were individually weighed (Mettler
XP2003S balance, Mettler Toledo, Greifensee, Switzerland). The mean tablet weight, and the relative
CV percentage values were then determined.
Hardness: determined using a Schleuniger Hardness Tester mod 6D as crushing force (N).
Tensile strength was also calculated to eliminate the possible effects of variations in tablet thickness on
the measured crushing force;
Disintegration time: evaluated using the T2 221 Erweka disintegration apparatus (Erweka GmbH,
Langen, Germany) at 37 ± 0.5 ◦C in pH 7.4 phosphate buffer;
Dissolution test: performed using a USP Paddle apparatus (Sotax AT7, Sotax, Thun, Switzerland).
Tablets were added to 900 mL of pH 7.4 phosphate buffer solution thermostated at 37 ± 0.5 ◦C, at a
stirring rate of 75 rpm. The concentration of dissolved drug was UV-monitored at 300 nm (Lambda 2
spectrophotometer, Perkin Elmer, Waltham, MA, USA). Each test was simultaneously carried out on six
samples. Dissolution efficiency (DE) was calculated from the area under the dissolution curve at time t
and expressed as a percentage of the area of the rectangle described by 100% dissolution in the same
time [50]. Percent of drug dissolved and DE values were analyzed by one-way analysis of variance
(ANOVA) followed by the Student–Newman–Keuls multiple comparison post-test (Graph Pad Prism
4.0 program, San Diego, CA, USA). Differences were considered statistically significant when p < 0.05.
3. Results and Discussion
3.1. Selection of the Solvents
The proper selection of the best solvent for the development of a liquisolid system, mainly based
on its solubilizing power towards the drug, is of critical importance to reduce the amount of solid
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adsorbent excipient, and, consequently, the final total weight of the dosage form. Then, as the first
step of this study, the solubilizing effect towards GLY of a wide variety of non-volatile, water-miscible
solvents (Labrasol®, Transcutol®, Solketal®, Kolliphor®HS15, 2-PYR, PEG 400, glycofurol, DMA,
benzyl benzoate and 1,3-butandiole), was evaluated. With this purpose, the minimal amount of each
solvent necessary to solubilize 5 mg GLY (therapeutic drug dosage) was determined. As shown in
Figure 1, DMA and 2-PYR emerged as the most effective solvents, requiring, respectively, only 0.025 or
0.050 mL to solubilize 5 mg drug, and then were chosen as the liquid vehicles for GLY liquisolid systems
preparation. The safe and effective use of 2-PYR as a solvent for drug solubilization has been reported,
in virtue of its lack of mutagenic or genotoxic activity [51], and its low developmental toxicity, and high
oral LD50 (5g/kg body weight in rats) (www.epa.gov/chemical-under-tsca). On the other hand, DMA is
approved by FDA as an excipient in parenteral and nasal spray products (www.accessdata.fda.gov) and
its safe use as a solubilizer, included also in intravenous pediatric formulations, has been proved [52–54].
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GLY stability in the selected solvents was verified, by checking its concentration at interval times up
to six months by spectrophotometric assay. No variations of drug concentration, and no modifications
of its UV curve were observed, indicative of drug stability and absence of degradation phenomena.
3.2. Characterization and Selection of Mesoporous Carriers as Adsorbent Carrier
The powder materials used as a carrier for pr paration of liquisolid systems should have high
liquid adsorbent power, and, at the same time, good flow and compaction properties, to allow uniform
feed and reproducible filling of tablet dies and good tableting. Then, the flow and compaction
properties of the mesoporous silicas and clay materials considered as potential adsorbent carriers
for preparation of liquisolid systems, namely Aeroperl®300, Zeopharm®5170 and Neusilin®US2,
were firstly investigated. The results of these studies, in terms of apparent and tapped density, Carr’s
Index and Hausner ratio, flowability (Copley test) and compactability (Wells test) are presented
in Table 1.
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Table 1. Apparent (DA) and tapped (DT) Density, Carr Index % (CI), Hausner Ratio (HR), flowability













Aeroperl®300 0.23 0.28 17.8 1.22 4 30 32 30
Neusilin®US2 0.17 0.20 16.5 1.19 4 390 400 400
Zeopharm®5170 0.32 0.34 6.2 1.07 4 15 16 16
Based on Carr’s Index and Hausner Ratio values, Zeopharm®5170 showed the best fluidity
level, followed by Neusilin®US2 and then by Aeroperl®300. However, according to the flow Copley
test, all powders presented excellent flowability, freely falling through the smallest apparatus hole
(4 mm diameter). As for the compaction properties, the results of the Wells test showed that all
powders samples exhibited a fragmenting behavior since similar crushing strength values were
obtained in the different conditions of the test (A≈B≈C). This is considered a desirable characteristic of
powders to be compressed, since the crushing strength of tablets made with fragmenting materials
should be less negatively affected by the presence of hydrophobic lubricant, such as Mg stearate,
with respect to plastic-deforming materials [55,56]. Neusilin®US2 gave rise to the tablets with the
highest hardness, but acceptable breaking strength values (around 30 N) were obtained also with
Aeroperl®300. On the contrary, the crushing strength values of Zeopharm®5170 tablets were very low,
probably due to its poor binding properties, and then this excipient was discarded in subsequent studies.
The selected mesoporous clay and silica were then further characterized by BET analysis.
Both compounds showed a very extended specific surface area, which confirmed their highly porous
nature. However, the chosen clay Neusilin®US2 showed a clearly greater surface area (355.5 vs.
268.4 m2/g) and also a significantly higher volume (1.0 vs. 0.5 cm3/g) of mesopores (i.e., pores in the
2.0–50 nm range) compared to the chosen silica Aeroperl®300.
3.3. Preparation and Characterization of Liquisolid Systems
Liquisolid systems were then prepared by dissolving 5 mg GLY (drug therapeutic single dose) in
0.05 mL of the selected solvents (DMA or 2-PYR), and then gradually adding, under continuous mixing,
Neusilin®US2 or Aeroperl®300, selected as carrier-coating materials. The strong adsorptive power of
the selected mesoporous clay and silica allowed to use a liquid load factor (i.e., the w/w ratio of liquid
medication to the carrier powder) of 1.1, clearly higher than the values commonly used in conventional
liquisolid systems [22,27,29,47], and obtain dry-looking powders, with practically unchanged flow
properties (measured according to the Copley flow test) compared to the respective pure carriers.
The obtained liquisolid systems were then characterized by LPS for granulometric distribution
and compared with the corresponding pure carriers. As can be observed in Figure 2, both Aeroperl®300
and Neusilin®US2 exhibited a satisfactorily homogeneous distribution curve, with a mean volumetric
diameter of 31 µm and 76 µm, respectively. The formation of liquisolid systems did not substantially
change the original granulometric distribution of the corresponding carriers, irrespective of the type
of solvent used, indicating in all cases the absence of appreciable aggregation phenomena and the
obtainment of homogeneous systems looking as dry powders.
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Figure 2. Granulometric analysis, by Laser Particle Size (LPS), of pure Aeroperl®300 and Neusilin®US2,
and of the corresponding liquisolid systems with glyburide (GLY) containing 2-pyrrolidone (2-PYR) or
dimetylacetamide (DMA) as non-volatile water miscible solvent.
DSC analyses were performed on pure drug and mesoporous clay and silica and on the
corresponding liquisolid systems, in order to evaluate possible solid-state modifications or interactions
between the components (Figure 3). The DSC curve of GLY was typical of a crystalline, pure, anhydrous
compound, showing a flat profile before the sharp endothermic peak at 175 ◦C (∆H 180 J/g) due to
the drug melting. On the contrary, the thermal curves of both carriers indicated their amorphous
nature, being characterized by a broad endothermal band in the range 70–140 ◦C, due to evaporation
of associated water molecules, followed, in the case of Neusilin®US2, by another endothermic effect at
a higher temperature (240 ◦C), due to decomposition phenomena.
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DSC curves of liquisolid systems containing 2-PYR as a solvent showed two broad endothermic
effects: the first, which peaked around 100 ◦C, was due to the carrier (Neusilin®US2 or Aeroperl®300)
dehydration, while the second one, which peaked around 240 ◦C, was due to the solvent evaporation
(boiling point 245 ◦C), partially superimposed, in the case of Neusilin®US2, to the carrier decomposition
phenomena. An analogous thermal behavior was displayed by liquisolid systems prepared with
DMA as a solvent; however, in this case, due to the lower boiling point of this solvent (165 ◦C),
a partial superimposition of the carrier dehydration band to that of solvent evaporation happened.
Interestingly, in all cases the complete disappearance of the drug melting peak was observed, which can
be considered indicative of drug amorphization and/or solubilization in the liquisolid system, i.e.,
its almost molecular dispersion within the liquisolid matrix [26,27].
The results of PXRD studies were substantially in agreement with those of DSC analysis. In fact,
as can be observed in Figure 4, the diffraction pattern of pure GLY exhibited the presence of numerous
sharp peaks, in particular at 18.8, 19.4, 20.8 and 22.9◦ 2Θ, indicative of its crystalline nature, while a
diffuse halo pattern, characteristic of amorphous powders, was shown by both mesoporous clay
and silica.
The typical diffraction peaks of the drug were no more detectable in the X-ray spectra of all the
liquisolid formulations, thus confirming the conversion of the drug in an amorphous or solubilized
form within the liquisolid matrix, as suggested by DSC analysis, and allowing to exclude any possible
artifact of this last technique, due to the sample heating during the scan.
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The ESEM outcomes (Figure 5) further supported the results of DSC and XRPD analyses. The ESEM
image of pure micronized GLY showed its crystalline nature and its very homogeneous particle size.
Neusilin®US2 appeared instead as particles of almost spherical form, with a highly porous surface,
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and Aeroperl®300 as spherical particles, many of which characterized by the presence of an internal
cavity. The morphology of liquisolid systems obtained with both Neusilin®US2 or Aeroperl®300 as
carrier-coating material was very similar to that of the corresponding pure samples, thus confirming
their excellent adsorbent power and the absence of agglomeration phenomena.
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Figure 5. ESEM images of pure glyburide (A), Aeroperl®300 (B) and Neusilin®US2 (C) and of the
corresponding liquisolid systems (B’ and C’).
Dissolution studies were then performed to evaluate the ability of the various liquisolid systems
to improve the GLY dissolution rate and select the more effective ones for the preparation of liquisolid
tablets. As can be seen in Figure 6, all the developed liquisolid systems showed a very marked
improvement of GLY dissolution rate compared to the plain GLY, with an about 27 times increase of
percent drug dissolved after only 2 min, and an about 4 times increase at the end of the test (60 min).
No statistically significant (p > 0.05) differences were found among the different kinds of liquisolid
systems and then they were all employed for tablet preparation.
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3.4. Preparation and Characterization of Liquisolid-Tablets
Preformulation studies, performed to select the most suitable excipients to use, in mixture with the
liquisolid systems, for obtaining direct-compressed tablets with the proper characteristics of hardness
and disintegration time, enabled the selection of two kinds of microcrystalline cellulose (Avicel®PH102
and Ceolus®KG802) as binders, in virtue of their high flowability and compressibility, and of Explotab®
(sodium starch glycolate) as super-disintegrant. The composition and properties of the examined
tablets are reported in Table 2. For each tablet formulation, the lowest compression force allowing to
obtain tablets with suitable hardness and tensile strength was used (Table 2). A conventional tablet
containing the drug as such was also prepared as a reference, by using the same excipients present in
liquisolid tablets, except the solvent, replaced by an equivalent quantity by weight of Avicel®PH102.
A GLY commercial tablet at the same drug dosage (Gliboral®) was also used as a further reference.
Table 2. Composition and properties of glyburide (GLY) liquisolid tablets.
Tablet
Code Ingredients (mg) Properties













LS1 5 55 – 55 – 44 20 10 0.5 3.4 62 1.42 50
LS2 5 55 – – 55 44 20 10 0.5 15 50 1.28 90
LS3 5 – 47 47 – 44 20 10 0.5 3.4 32 0.85 60
4 – 47 – 47 44 20 10 0.5 15 29 0.79 85
All tablets complied with the USP friability test (weight loss in all cases less than 0.2%) and weight
uniformity and showed short disintegration times, always less than 2 min.
Dissolution test was perform d under the same experimental condition (900 mL of pH 7.4
buffer soluti n) used in our previous studies a med at the deve opment of GLY fast-dissolving
tablets [12,15,16,20], in order to obtain comparable results. Mor over, these conditions of medium
volume and pH are those indicated by FDA and USP (test 5, Revision Bulletin 2010, 1st Supplement
USP 34-NF 29) for the dissoluti n test of GLY (micronized) tablets. The dis olution profiles of GLY
from liquisolid-tablets are shown in Figure 7, in comparison with those from the conventional reference
and the marketed tablets, while their dissolution parameters, in terms of percentage drug dissolved
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and Dissolution Efficiency (DE) at 10 min and 60 min, indicative, respectively, of the rate and of the
totality of the process, are collected in Table 3.
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Figure 7. Dissolution profiles of glyburide (GLY) from liquisolid tablets (LS 1–4) and from the
commercial tablet (Gliboral®) and the reference conventional tablet (CT).
Table 3. Dissolution parameters of glyburide from liquisolid (LS) and conventional (CT) tablets in
terms of percent dissolved (PD) and dissolution efficiency (D.E.) at 10 and 60 min.
Tablet Code * PD10 PD60 DE10 DE60
LS1 91.8 98.1 58.1 90.4
LS2 88.6 96.3 55.9 88.1
LS3 81.3 92.1 47.1 82.7
LS4 79.6 91.4 46.8 81.5
CT 27.5 40.7 15.1 33.4
* For the composition of tablet batches, see Table 2.
As is evident, all liquisolid tablets exhibited a marked enhancement of the GLY dissolution
performance, with respect to both the reference tablet containing the plain drug and the commercial
tablet. In fact, the percentage of drug dissolved at 60 mi from the conventional reference and
from the commercial tablets reached only 40% and 50%, respectively, while it exceeded 90% for all
liquis lid systems. The observe improveme t in dissolution rate can be attributed to the increased
wetting properties and t the larger surface area of rug particles exposed to the dissolution medium,
in virtue of its almost molecular dispersion within the liquisolid matrix [26–28]. However, interestingly,
tablets with liq is lid systems c ntaining 2-PYR as solvent showed a slightly better dissolution
profile, particularly in terms of percentage dissolved at 10 min (p < 0.05), than those containing DMA,
espite the slightly higher solubility of GLY in DMA than in 2-PYR (see Figure 1). Nevertheless,
this result may be somehow connected to the tablet formulation and/or compression process. In fact,
dissolution experiments performed directly on the plain liquisolid systems as pow ers, exhibited a
inverted behavior, with a slight, even not significant, better performance of those containing DMA as
solvent (see Figure 6).
On the other hand, no sig ificant differences (p > 0.05) in the drug dissolution behavior were
instead observed between systems with Neusilin®US2 or Aeroperl®300. However, as can be seen in
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Table 2, when comparing liquisolid formulations containing the same solvent (LS1 vs. LS2, or LS3 vs.
LS4), Neusilin®US2 allowed to obtain tablets with similar or even better hardness, than those with
Aeroperl®300, but using lower compression force. This is considered a desirable property, since tablets
of suitable hardness, necessary to avoid breakage problems, should be ideally obtained without
applying excessive compression force, in order to can be easily disintegrated when in contact with
the dissolution medium. In fact, tablets prepared under large compression force will have a reduced
porosity and will require more time for water penetration into the compact, thus resulting in prolonged
disintegration times [27].
A comparison between the drug dissolution properties from the new liquisolid tablets and
those from the previously developed GLY fast-dissolving tablets based on other different formulation
approaches, showed that the new technology was actually more effective in enhancing the GLY
dissolution properties than the formation of binary or ternary solid dispersions [15,16], cyclodextrin
complexation [12] or simple adsorption on mesoporous silicas [46]. The performance of the
new GLY liquisolid tablets resulted comparable only to that of fast-dissolving tablets based on
solid-self-microemulsifying systems (SMEDDS) [20]. However, the new liquisolid-tablets presented
the strong advantage of a simpler and faster formulation development and of a lower production cost.
In fact, they did not require the time-consuming construction of pseudo-ternary phase diagrams to
select the best surfactant and co-surfactant and to define the zone of microemulsion existence, which are
instead necessary for the SMEDDS development. On the contrary, their very basic preparation
procedure should assure an easy and economic industrial scale-up feasibility.
Finally, ESEM analyses were performed on final liquisolid tablets (Figure 8). The results further
confirmed the better technological performance of tablets containing Neusilin®US2, whose whole
surface appeared highly porous but perfectly homogeneous (Figure 8A); on the contrary, some horizontal
fracture lines and thin fissures were observed on the surface of tablets containing Aeroperl®300,
indicative of not optimal technological properties of the formulation and of a potential tablet
delamination process (Figure 8B).
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4. Conclusions
New liquisolid-tablet formulations of GLY, based on the use of a mesoporous clay (Neusilin®US2)
or silica (Aeroperl®300), were successfully developed.
Both the selected mesoporous clay and silica, in virtue of their very marked adsorbent power joined
to excellent flow and compactability properties, allowed to replace the use of combinations of carrier
and coating materials, which are instead commonly employed for the preparation of conventional
liquisolid systems.
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The use of 2-PYR and DMA as very powerful solvents towards GLY (never employed before,
to the best of our knowledge, in liquisolid formulations), enabled to strongly reduce the solvent volume
necessary (0.05 mL) to completely dissolve the drug therapeutic dose (5 mg). Moreover, the selected
highly-porous clay (Neusilin®US2) and silica (Aeroperl®300) enabled a high liquid load factor (1.1),
because of their small amount necessary to convert drug solutions into well-flowable powders.
All the obtained liquisolid-tablets exhibited satisfying technological properties and exhibited a
marked improvement of GLY dissolution properties, allowing in all cases to overcome 90% of dissolved
drug after 60 min, with respect to only 40% obtained with the reference formulation containing the
plain drug. However, the mesoporous clay Neusilin®US2 showed a superior performance with
respect to the mesoporous silica Aeroperl®300 since it allowed to obtain tablets with more suitable
technological properties.
The improved GLY dissolution behavior was attributed to its increased wetting properties and
surface area, in virtue of its solubilization or almost molecular dispersion within the liquisolid matrix,
as confirmed by DSC and PXRD studies.
In conclusion, the proposed strategy offers the benefits not only of simplifying the liquisolid
formulation development, reducing the number of components, but also, and above all, of considerably
increasing the liquid loading capacity, thus strongly reducing the amount of adsorbent material
necessary to obtain dry-looking, freely-flowing powders, and ultimately decreasing the final tablet
weight. Finally, simplicity, ease of handling, high cost-effectiveness of the proposed approach, make it
particularly advisable for a possible industrial scale-up.
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